Info

🌱來自: renal-cell-carcinoma

mTOR inhibitors

**1° endpoint(s) listed below include PFS, OS at interim analysis Class S/E: Stomatitis, fatigue, rash, edema, pneumonitis, hyperglycemia, hyperlipidemia, ↓ WBC, ↓ PLT Everolimus (Lancet 2008;372:449) vs. placebo: PFS: 4 mos vs. 1.9 mos (HR: 0.30, P <0.0001) Temsirolimus (NEJM 2007;356:2271) vs. IFNα: OS: 10.9 mos vs. 7.3 mos (HR: 0.73, P = 0.008)

Siblings

• Epidemiology
• Histology and molecular biology
• Hereditary RCC and germline testing
• Clinical presentation
• Staging (TNM classification) and prognosis
• Treatment principles
• Systemic therapy for metastatic clear cell RCC
• Second-line therapies
• Combined-modality therapies
• Tyrosine kinase inhibitors
• Immunotherapies
• mTOR inhibitors
• Non-clear cell histology